Literature DB >> 16969077

CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation.

Leonard J Appleman1, Irina Chernova, Lequn Li, Vassiliki A Boussiotis.   

Abstract

Activation through TCR/CD3-plus-CD28 induces primary T lymphocytes to enter S phase. Downregulation of cyclin-dependent kinase inhibitor p27(kip1) is critical in this process and is mediated by ubiquitin-targeted degradation of p27(kip1). Ubiquitination of p27(kip1) is performed by the SCF(skp2) ubiquitin ligase comprised of the core components Roc1, Cul1 and Skp1 and the substrate recognition components Skp2 and Cks1. Here we show that in primary human T lymphocytes, the SCF(skp2) core components Roc1, Cul1 and Skp1 are constitutively expressed, and their levels remain unchanged upon TCR/CD3-plus-CD28 costimulation. In contrast, the substrate recognition components Skp2 and Cks1 are almost undetectable in resting T cells and are transcriptionally induced upon costimulation. We determined that the SKP2 promoter lies directly upstream of the translational start site and contains binding sites for SP1, Elk-1 and E2F transcription factors. Mutagenesis of SP1 and Elk-1 sites abrogated TCR/CD3-plus-CD28-mediated SKP2 promoter-driven reporter activity, whereas mutagenesis of an E2F site enhanced reporter activity, suggesting that SKP2 promoter may act as a node of integration for mitogenic and anti-mitogenic signals. Thus, in primary T lymphocytes CD28 costimulation can directly regulate cell cycle progression by inducing transcription of the substrate recognition components of SCF(skp2) ubiquitin ligase that targets p27(kip1) for degradation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969077     DOI: 10.4161/cc.5.18.3139

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  17 in total

Review 1.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

2.  Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex.

Authors:  J Wu; S-W Lee; X Zhang; F Han; S-Y Kwan; X Yuan; W-L Yang; Y S Jeong; A H Rezaeian; Y Gao; Y-X Zeng; H-K Lin
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

3.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

4.  Cell cycle arrest caused by MEK/ERK signaling is a mechanism for suppressing growth of antigen-hyperstimulated effector T cells.

Authors:  Shizuka Ohtsuka; Shuhei Ogawa; Ei Wakamatsu; Ryo Abe
Journal:  Int Immunol       Date:  2016-08-19       Impact factor: 4.823

Review 5.  Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.

Authors:  Maria I Carlo; Martin H Voss; Robert J Motzer
Journal:  Nat Rev Urol       Date:  2016-06-21       Impact factor: 14.432

6.  Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Authors:  Clara Curiel-Lewandrowski; Hisato Yamasaki; Chuan Ping Si; Xiaoyi Jin; Yujun Zhang; Jillian Richmond; Marina Tuzova; Kevin Wilson; Beth Sullivan; David Jones; Nataliya Ryzhenko; Frederick Little; Thomas S Kupper; David M Center; William W Cruikshank
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

7.  In CD28-costimulated human naïve CD4+ T cells, I-κB kinase controls the expression of cell cycle regulatory proteins via interleukin-2-independent mechanisms.

Authors:  Elisa Lupino; Barbara Buccinnà; Cristina Ramondetti; Annarosa Lomartire; Giovanni De Marco; Emanuela Ricotti; Pier-Angelo Tovo; Maria T Rinaudo; Marco Piccinini
Journal:  Immunology       Date:  2010-10       Impact factor: 7.397

Review 8.  Biochemical signaling of PD-1 on T cells and its functional implications.

Authors:  Vassiliki A Boussiotis; Pranam Chatterjee; Lequn Li
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

9.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

Review 10.  The Skp2 Pathway: A Critical Target for Cancer Therapy.

Authors:  Zhen Cai; Asad Moten; Danni Peng; Che-Chia Hsu; Bo-Syong Pan; Rajeshkumar Manne; Hong-Yu Li; Hui-Kuan Lin
Journal:  Semin Cancer Biol       Date:  2020-02-01       Impact factor: 17.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.